Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Retained Earnings (2016 - 2026)

Ani Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at $1.0 million for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 101.03% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 101.03% increase, with the full-year FY2025 number at $1.0 million, up 101.03% from a year prior.
  • Retained Earnings hit $1.0 million in Q4 2025 for Ani Pharmaceuticals, up from -$50.6 million in the prior quarter.
  • Over the last five years, Retained Earnings for ANIP hit a ceiling of $13.7 million in Q2 2023 and a floor of -$100.3 million in Q4 2024.
  • Historically, Retained Earnings has averaged -$45.9 million across 5 years, with a median of -$56.5 million in 2024.
  • Biggest five-year swings in Retained Earnings: plummeted 1257.31% in 2022 and later skyrocketed 152.78% in 2023.
  • Tracing ANIP's Retained Earnings over 5 years: stood at -$47.8 million in 2021, then plummeted by 103.68% to -$97.3 million in 2022, then rose by 17.63% to -$80.1 million in 2023, then dropped by 25.14% to -$100.3 million in 2024, then skyrocketed by 101.03% to $1.0 million in 2025.
  • Business Quant data shows Retained Earnings for ANIP at $1.0 million in Q4 2025, -$50.6 million in Q3 2025, and -$76.9 million in Q2 2025.